Davita Inc. Stock
Davita Inc. Stock
Davita Inc. shows a slight decrease today, losing -€0.150 (-0.120%) compared to yesterday.
The community is currently still undecided about Davita Inc. with 2 Buy predictions and 0 Sell predictions.
On the other hand, the target price of 124 € is below the current price of 124.1 € for Davita Inc., so the potential is actually -0.08%.
Our community identified positive and negative aspects for Davita Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Davita Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Davita Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Davita Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Davita Inc. | -0.120% | 3.763% | -0.081% | 55.514% | 31.434% | 32.190% | 158.488% |
| Amn Healthcare Svs | 0.960% | 0.962% | -10.256% | -33.544% | -21.642% | -17.969% | 19.918% |
| Chemed Corp. | 0.900% | -0.885% | -5.085% | 9.804% | 7.692% | 45.078% | 93.370% |
| Select Medical Holdings | 0.780% | 1.575% | -3.731% | -1.527% | 19.444% | -15.686% | 110.681% |
Comments
DaVita Inc. (NYSE: DVA) had its price target raised by analysts at UBS Group AG from $113.00 to $134.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DVA provided by MarketBeat
DaVita Inc. (NYSE: DVA) had its price target lowered by analysts at UBS Group AG from $142.00 to $113.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DVA provided by MarketBeat